
MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
The Field Sales Trainer is responsible for driving field force capability development through field coaching, training reinforcement, and National-level pull-through of commercial initiatives. This role partners closely with the National Director, Area Business Directors, Marketing, and Commercial Training to identify performance opportunities, reinforce effective selling behaviors, and support consistent execution of brand strategy across the field sales organization.
The Field Sales Trainer serves as a critical link between field execution and cross-functional commercial strategy by providing insights and feedback on marketing messaging, field strategy, selling skills, field team development opportunities, and training effectiveness.
Assigned Area: National
JOB FUNCTIONS/RESPONSIBILITIES
Field Coaching and Sales Capability Development
The Field Sales Trainer will provide in-field coaching and development support to enhance field team effectiveness, execution quality, and customer engagement.
Responsibilities include:
National-Level Strategy Pull-Through
The Field Sales Trainer will support execution of commercial, marketing, and training initiatives at the National level.
Responsibilities include:
Insights, Feedback, and Gap Identification
The Field Sales Trainer will provide meaningful insights to leadership and cross-functional partners regarding field execution and market dynamics.
Responsibilities include:
Cross-Functional Collaboration
The Field Sales Trainer will work closely with commercial leadership and internal partners to support aligned execution.
Responsibilities include:
Compliance and Operational Excellence
The Field Sales Trainer is expected to operate with a high degree of professionalism, integrity, and compliance.
Responsibilities include:
QUALIFICATIONS
Education/Experience:
PREFERRED REQUIREMENTS
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.